Why is Gland Pharma falling/rising?

As of 09-Jul, Gland Pharma Ltd's stock price is currently at 1,874.70, reflecting a decrease of 15.3 points or 0.81%. The stock has recently underperformed its sector by 1.01% and has experienced a trend reversal after four consecutive days of gains. Despite this decline, Gland Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend in the longer term. Over the past month, the stock has risen by 13.76%, although it has seen a year-to-date increase of only 4.81% and a year-over-year decline of 7.54%. The company benefits from a low debt-to-equity ratio and high institutional holdings at 40.18%, suggesting that it has a solid financial foundation and is viewed favorably by more knowledgeable investors.
In the broader market context, Gland Pharma's short-term performance of +0.45% over the past week outpaces the Sensex's modest gain of +0.15%. However, the stock's longer-term performance has been less favorable, with a significant decline of 25.69% over the past three years compared to the Sensex's impressive growth of 53.33%. The rising investor participation, indicated by a 128.23% increase in delivery volume, suggests that there is still interest in the stock despite its recent price drop. Overall, while Gland Pharma shows some positive indicators, the recent price decline reflects a temporary setback amid a generally volatile market environment.